GPCR
Structure TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Bull case assumes successful clinical readouts, one or more strategic partnerships, and meaningful uptake of lead oral GPCR-targeted therapy, driving re-rating toward peers and multiples seen in commercial-stage specialty biotech.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +9.2.
What can break
Capital raise dilution
Momentum
84
Value
41
Sentiment
15
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $32.00 · Bull $45.00 · Bear $18.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2025-10-31 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $106.53
Why
Momentum84 · Δ7d +9.2
Value41 · Δ7d -0.1
Sentiment15 · Δ7d +4.8
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
84
26% active weight
Current posture
7d trendImproving
Δ7d
+9.2
Δ21d
+29.6
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
15
34% active weight
Current posture
7d trendImproving
Δ7d
+4.8
Δ21d
+0.3
Why this grade
Composite grade D. Momentum 84.4 / Value 41.1 / Sentiment 14.9
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$3.45B
Beta
-
Shares Out
71.07M
P/E (TTM) · Derived
-20.3
P/S (TTM)
-
P/FCF (TTM) · Derived
-17.45
Rev YoY
-
EPS YoY
+28.6%
Gross Margin
-
Op Margin
-
Net Debt
-$1.44B
Current Ratio
26.16
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology